<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> has been shown to increase hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production and decrease insulin sensitivity </plain></SENT>
<SENT sid="1" pm="."><plain>Patients who utilize either an <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> (ACEI) or angiotensin receptor blocker (ARB) may experience a decreased incidence of new-<z:hpo ids='HP_0003674'>onset</z:hpo> type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Three reviewers conducted a systematic literature search of Medline, EMBASE, CINAHL, and the Cochrane Library (1966 to present) to extract a consensus of trial data involving an ACEI or ARB with an end point of new-<z:hpo ids='HP_0003674'>onset</z:hpo> type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Studies were included if they were randomized controlled trials verses placebo/routine therapy </plain></SENT>
<SENT sid="4" pm="."><plain>A random-effects model was utilized </plain></SENT>
<SENT sid="5" pm="."><plain>Subgroup and sensitivity analyses were conducted </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Eleven trials were identified, including 66,608 patients </plain></SENT>
<SENT sid="7" pm="."><plain>An ACEI or ARB prevented new-<z:hpo ids='HP_0003674'>onset</z:hpo> type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (odds ratio 0.78 [95% CI 0.73-0.83]) </plain></SENT>
<SENT sid="8" pm="."><plain>The influence of either an ACEI (six trials) or an ARB (five trials) alone on new-<z:hpo ids='HP_0003674'>onset</z:hpo> type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> was similar (0.79 [0.71-0.89] and 0.76 [0.70-0.82], respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>Regardless of indication for use, <z:hpo ids='HP_0000822'>hypertension</z:hpo> (seven trials), <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (two trials), or <z:hpo ids='HP_0001635'>heart failure</z:hpo> (two trials), reductions in new-<z:hpo ids='HP_0003674'>onset</z:hpo> type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were maintained (0.79 [0.72-0.85], 0.76 [0.60-0.95], and 0.70 [0.50-0.96], respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>No statistical <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> was observed for any evaluation (P &gt; 0.1 for <z:hpo ids='HP_0000001'>all</z:hpo> comparisons) </plain></SENT>
<SENT sid="11" pm="."><plain>ACEIs and ARBs did not reduce the odds of mortality, cardiovascular, or cerebrovascular events versus control therapy among <z:hpo ids='HP_0000001'>all</z:hpo> of these studies combined or the <z:hpo ids='HP_0000822'>hypertension</z:hpo> trials </plain></SENT>
<SENT sid="12" pm="."><plain>ACEIs and ARBs did reduce the odds of these outcomes among the <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> studies versus control therapy </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: ACEIs or ARBs may decrease patients' odds of developing new-<z:hpo ids='HP_0003674'>onset</z:hpo> type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> but does not reduce the odds of mortality, cardiovascular, or cerebrovascular outcomes over the study follow-up periods among patients with <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
</text></document>